Ra Pharmctl Inc (RARX) Given Average Rating of “Buy” by Brokerages
Shares of Ra Pharmctl Inc (NASDAQ:RARX) have earned an average recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $25.60.
Several research firms have recently commented on RARX. Zacks Investment Research cut shares of Ra Pharmctl from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Jefferies Group LLC reissued a “buy” rating and set a $25.00 price target on shares of Ra Pharmctl in a research note on Friday, July 14th. Finally, Royal Bank Of Canada began coverage on shares of Ra Pharmctl in a research note on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target on the stock.
Shares of Ra Pharmctl (RARX) opened at 14.44 on Monday. The firm’s market capitalization is $326.47 million. The firm has a 50-day moving average price of $14.68 and a 200-day moving average price of $14.68. Ra Pharmctl has a 52-week low of $12.05 and a 52-week high of $27.84.
Ra Pharmctl (NASDAQ:RARX) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06). On average, equities research analysts anticipate that Ra Pharmctl will post ($2.31) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Ra Pharmctl Inc (RARX) Given Average Rating of “Buy” by Brokerages” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/09/ra-pharmctl-inc-rarx-given-average-rating-of-buy-by-brokerages.html.
A number of hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its stake in Ra Pharmctl by 30.6% in the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after acquiring an additional 2,543 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in Ra Pharmctl by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after acquiring an additional 3,859 shares during the last quarter. California State Teachers Retirement System boosted its stake in Ra Pharmctl by 26.1% in the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock valued at $390,000 after acquiring an additional 4,300 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Ra Pharmctl by 7.0% in the second quarter. Goldman Sachs Group Inc. now owns 73,103 shares of the company’s stock valued at $1,370,000 after acquiring an additional 4,751 shares during the last quarter. Finally, American International Group Inc. bought a new position in Ra Pharmctl in the first quarter valued at approximately $102,000. 66.26% of the stock is currently owned by hedge funds and other institutional investors.
Ra Pharmctl Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Stock Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related stocks with our FREE daily email newsletter.